AAM Warns Over Weakening 180-Day Incentive
Proposals as part of the latest US budget to amend provisions around the 180-day exclusivity incentive for generics could risk weakening the critical driver of competition, the AAM has warned.
Proposals as part of the latest US budget to amend provisions around the 180-day exclusivity incentive for generics could risk weakening the critical driver of competition, the AAM has warned.